---
schema_version: "secwatch.filing_event.v1"
accession: "0001396814-24-000010"
form_type: "8-K"
ticker: "PCRX"
cik: "0001396814"
company_name: "Pacira BioSciences, Inc."
filed_at: "2024-01-04T23:59:59+00:00"
generated_at: "2026-06-07T03:53:42.429222+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Pacira reports preliminary FY2023 revenue of $675.0M, up 1.2% YoY; Q4 EXPAREL sales $143.9M

## Summary
- FY2023 total revenue $675.0M vs $666.8M in FY2022, driven by EXPAREL ($538.1M), ZILRETTA ($111.1M), iovera° ($19.7M).
- Q4 2023 EXPAREL net sales $143.9M (+4.3% YoY); ZILRETTA $28.7M (+2.5%); iovera° $6.0M (+30%).
- ExPAREL full-year average daily volume growth of 5%, offset by lower net selling price from 340B and other contracts.
- Company plans to launch EXPAREL in two lower extremity nerve blocks in 2024 and expects NOPAIN Act expansion in 2025.
- Preliminary, unaudited figures; complete Q4/FY results with 2024 guidance expected in Q1 2024.

## SEC filing metadata
- accession: 0001396814-24-000010
- form_type: 8-K
- ticker: PCRX
- cik: 0001396814
- company_name: Pacira BioSciences, Inc.
- filed_at: 2024-01-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1396814/000139681424000010/0001396814-24-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1396814/000139681424000010/pcrx-20240104.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001396814-24-000010
- JSON: https://secwatch.observer/filing/0001396814-24-000010.json
- Plain text: https://secwatch.observer/filing/0001396814-24-000010.txt

## Key facts
- Earnings Releases
  Pacira BioSciences, Inc. reported full-year ended December 31, 2023 results: revenue $675.0 million.
  - Period: full-year ended December 31, 2023
  - Revenue: $675.0 million
  - Result: preliminary results
  source text: Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited total revenue of $675.0 million for the year ended December 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1396814/000139681424000010/0001396814-24-000010-index.htm
- Earnings Releases
  Pacira BioSciences, Inc. reported preliminary financial results for fourth quarter ended December 31, 2023.
  - Period: fourth quarter ended December 31, 2023
  - Result: preliminary results
  source text: On January 4, 2024, Pacira BioSciences, Inc. issued a press release announcing its preliminary unaudited revenue for the fourth quarter and full-year ended December 31, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1396814/000139681424000010/0001396814-24-000010-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.